Quest Diagnostics Q1 2026: Revenue Rises on Consumer and Clinical Drives, and Nova Looms Over the Cash Register
Ticker: DGX; EPS growth and a higher revenue forecast reshape expectations for Quest Diagnostics and peers in the diagnostics space.
Overview: The Quarter in Numbers
Quest Diagnostics Incorporated (NYSE: DGX) reported results for the first quarter ended March 31, 2026. The company posted first-quarter revenue of $2.90 billion, a 9.2% increase versus the prior year, with organic growth of 9.0%. On the bottom line, the quarter produced diluted earnings per share (EPS) of $2.24, up 15.5% from 2025, and adjusted diluted EPS of $2.50, up 13.1% year over year.
The numbers land in a framework where EPS and revenue trajectory matter as much as the product mix: Quest is signaling a continued push into consumer-facing channels, digital tools, and higher-margin diagnostic innovations while maintaining the discipline that a capital-intensive services business requires.
Guidance and Market Expectations
For full-year 2026, Quest raised its expectations, guiding diluted EPS to a range of $9.58 to $9.78 and adjusted diluted EPS to $10.63 to $10.83. Management characterized the quarter as evidence of robust execution and reaffirmed the company’s plan to sustain double-digit advances in certain diagnostics segments, supported by product and service innovations already in motion.
In investor terms, this translates to a firmer revenue forecast pathway than before and a tilt toward higher earnings quality, especially given the mix shift toward consumer health initiatives and higher-value laboratory tests. Analysts will now calibrate their EPS consensus and revenue forecasts against this updated trajectory, watching how the company sustains the 9% revenue growth rate and whether the adjusted EPS lift can outpace any cost headwinds from expansion activities.
Strategic Highlights: Where Quest is Putting Its Chips
Serving Clinicians and Health Systems
Quest highlighted continued governance of care delivery pathways through operational partnerships. Notably, it expanded its Co-Lab Solutions initiative with Corewell Health, a major health system in Michigan, signaling a broader adoption of integrated laboratory services and collaborative ventures. The company also referenced scaling its lab and water-purity testing solutions across multiple dialysis clinics and hospitals, extending reach beyond the dialysis clinics previously operated by Fresenius Medical Care in the United States.
Serving Consumers
On the consumer side, Quest emphasized growth through questhealth.com and collaborations with top consumer health brands. This channel expansion aligns with a broader industry trend toward consumer access to lab insights, enabling patients to engage with their data outside traditional clinical settings.
Delivering Diagnostic Innovations
In Advanced Diagnostics, Quest reported double-digit revenue growth and highlighted the Quest AD-Detect® blood tests for Alzheimer’s disease, among other cardiometabolic and endocrine testing areas. A notable collaboration with City of Hope aims to study Haystack MRD® as an aid in cancer monitoring and treatment decisions across four solid tumor cancers at 14 U.S. sites. The quantity and breadth of these partnerships point to a strategic pivot from pure testing volume toward higher-value diagnostics and data-driven care decisions.
Driving Operational Excellence
Quest rolled out its AI Companion tool to help patients better understand their lab test reports, reporting roughly 350,000 engagements since its rollout in the current quarter. This effort underscores a push to convert lab data into usable, patient-facing insights, potentially improving patient engagement and satisfaction while positioning Quest as a data-enabled service platform rather than a traditional lab only.
Project Nova: Modernizing the Order-to-Cash Engine
The company also outlined its planning and design work for Project Nova, a multi-year initiative to transform order-to-cash processes and systems, with the first wave of solutions slated for rollout in fall 2027. If successful, Nova could deliver faster cash cycles and better working capital management—an important consideration for a business with substantial clinical and laboratory infrastructure.
What This Might Portend for Quest and Its Peers
The Q1 results reflect a company leveraging multiple levers: steady organic growth, a pivot to higher-margin diagnostics, and a clear push into consumer-facing data and AI-enabled tools. The EPS beat (relative to prior periods) and the raised revenue guidance are not a single-quarter anomaly so much as a signal that Quest is investing in the platforms it will need to compete in a more integrated, software-enabled diagnostics ecosystem.
For the sector, several threads emerge. First, partnerships and co-lab arrangements with health systems could become a more prevalent model for scale, particularly in markets where capital for standalone labs is constrained or where clinical systems seek integrated data solutions. Second, consumer-facing channels and digital platforms may drive incremental demand and data that unlocks monetization beyond traditional testing volumes, potentially improving the earnings mix as tests are complemented by software-enabled services. Third, AI-enabled patient communications and operational tools may compress cycle times, improve outcomes, and support more defensible pricing through value-based care narratives.
Of course, this is not without risk. Reimbursement dynamics, price competition among large lab networks, and the regulatory tailwinds or headwinds around data-enabled care and AI health tools could shape the sustainability of these gains. The Nova project, if successful, could meaningfully impact cash conversion and working capital—areas investors scrutinize for quality of earnings as much as for growth in revenue.
Implications for Sector Peers
Competitors may feel pressure to accelerate their own consumer health strategies, AI-enabled customer support tools, and collaborative lab ventures. A shift toward higher-value diagnostics and faster, more transparent access to data could become a differentiator, particularly as customers—ranging from clinicians to patients—davor (to borrow a line) more control over care pathways.
Analysts will watch whether the EPS consensus for Quest adjusts upward in response to the guidance raise and whether the revenue forecast for 2026 trends higher as the company leans into its Nova program and consumer platforms. In the meantime, Quest’s stock may benefit from a narrative that blends traditional lab scale with modern software-enabled health services.
Risks and What to Watch
The year ahead hinges on execution across partnerships, innovation adoption, and cost discipline. Digestible consumer engagement, the durability of organic growth, and the ability to translate AI-driven insights into measurable improvements in outcomes and margins will be critical. Any friction in integrating Nova or in expanding Co-Lab collaborations could temper the optimism embedded in these numbers.
Conclusion: A Diagnostics Company Recalibrating for the Long Run
Quest Diagnostics is signaling that it intends to be more than a high-volume lab operator. By weaving together consumer channels, strategic partnerships, diagnostic innovations, and AI-powered patient engagement, the company is attempting to convert revenue growth into durable earnings power. The Q1 results offer a glimpse of that trajectory, with a better EPS backdrop, a lifted revenue forecast, and a slate of initiatives designed to broaden Quest’s role in the care continuum—and possibly reset expectations for the broader diagnostic lab landscape.
For investors and sector peers watching the pace of change in health information and diagnostic services, Quest’s quarter is a reminder that the money in diagnostics is increasingly tied to platforms, data, and partnerships as much as to tests themselves.